The ER antagonist properties of tamoxifen are evident in its ability to reduce the risk of breast cancer mortality by almost one-third (7), whereas its agonist properties are largely responsible for the increased risk of endometrial cancer associated with long term use (9). The gene discussed is ESR1; the disease is breast carcinoma.